Total amount raised
$300 Millions
Latest funding date
3/1/2018
Location
Helix has successfully raised significant capital through multiple funding rounds, with notable investors such as DFJ Growth and Warburg Pincus. The company integrates genomics into healthcare systems, aiming to make genetic information accessible and actionable.
Keep reading to explore the intricacies of Helix's fundraising journey and the investors backing this transformative platform.
What Is Helix?
Helix, founded on July 15, 2015, by James Lu, Justin Kao, and Scott Burke, is a population genomics company based in San Mateo, California. The company aims to advance genomics research and integrate genomic data into clinical care. With a team of 101-250 employees, Helix provides an end-to-end platform that supports health systems, life sciences companies, and payers in leveraging genomic data for various applications.
How Much Funding Has Helix Raised?
- Series A
- Amount Raised: $100M
- Date: August 2015
- Lead Investors: Illumina
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To launch the company and develop its initial genomics platform.
- Venture Round
- Amount Raised: $20M
- Date: October 2017
- Lead Investors: Kleiner Perkins
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand the company's research and development capabilities.
- Series B
- Amount Raised: $200M
- Date: March 2018
- Lead Investors: DFJ Growth
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale operations and enhance the genomics platform.
- Grant
- Amount Raised: $33M
- Date: July 2020
- Lead Investors: National Institutes of Health
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support COVID-19 testing and viral surveillance efforts.
- Series C
- Amount Raised: $50M
- Date: June 2021
- Lead Investors: Warburg Pincus
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate the population genomics platform and continue COVID-19 testing efforts.
Total Amount Raised: $403M. Current Valuation: Not publicly disclosed.
Key Investors
- DFJ Growth
- Details: DFJ Growth is a venture capital firm that invests in high-growth technology companies. They have a history of backing transformative companies in various sectors.
- Investment Focus Areas: Technology, healthcare, energy.
- Notable Investments: SpaceX, Tesla, Twitter.
- Warburg Pincus
- Details: Warburg Pincus is a global private equity firm focused on growth investing. They have a diverse portfolio across multiple industries.
- Investment Focus Areas: Healthcare, technology, financial services.
- Notable Investments: CrowdStrike, Avalara, Reorg.
- National Institutes of Health
- Details: The National Institutes of Health (NIH) is a part of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting medical research.
- Investment Focus Areas: Medical research, public health, healthcare innovation.
- Notable Investments: Various healthcare startups and research initiatives.
- Kleiner Perkins
- Details: Kleiner Perkins is a venture capital firm specializing in investments in early-stage and growth companies. They have a strong track record in the technology and healthcare sectors.
- Investment Focus Areas: Technology, healthcare, life sciences.
- Notable Investments: Google, Amazon, Genentech.
- Illumina
- Details: Illumina is a leading developer and manufacturer of life science tools and integrated systems for large-scale analysis of genetic variation and function.
- Investment Focus Areas: Genomics, biotechnology, healthcare.
- Notable Investments: Various genomics and biotechnology companies.
What's Next for Helix?
Helix stands at the cusp of significant growth, driven by the expansion of its population genomics platform across health systems and life sciences companies. The ongoing demand for COVID-19 testing and viral surveillance further amplifies their potential. With a recent $50 million Series C funding, Helix is well-positioned to capitalize on these opportunities.
Future fundraising efforts seem likely as Helix continues to scale its operations and develop new genomic tests. However, the company must navigate regulatory challenges and maintain data security to ensure sustained growth. Competition in the genomics space also poses a potential hurdle, but Helix's innovative platform and strategic partnerships could help mitigate these risks.
Use Clay to Get Funding Data
Sales professionals, take your strategy to the next level by leveraging Clay's platform to access comprehensive fundraising data on companies like Helix and gather other critical business insights.
Sign up for free on Clay and start transforming your sales approach today.
